Center for Early Molecular Diagnosis and Precision Intervention (Precision Medicine)
The center is at the forefront of pioneering research in salivary protein fingerprinting and quantitative proteomics technology for molecular diagnosis in China. It has successfully established methods and a technological platform for salivary proteomics, driving a new field in integrative molecular medicine combining traditional Chinese and Western medicine. The center applies these technologies to diagnose various major chronic diseases, offering extensive research prospects and significant clinical value.
Key Research Directions:
Disease-Specific Salivary Proteomics:
Initiated studies on the variations in salivary proteomes across different diseases, leading to new insights in micro-diagnostic traditional Chinese medicine.
Developed non-invasive molecular diagnostic biomarkers for diseases such as gastric cancer, colorectal cancer, liver cancer, breast cancer, thyroid cancer, chronic gastritis, chronic nephritis, and diabetes.
Established high-sensitivity and specificity non-invasive molecular diagnostic models for various diseases, expanding the technical scope of integrative clinical diagnostics.
Molecular Medicine Techniques:
Employs genetic polymorphism, genome sequencing, epigenetics, miRNA, and proteomics to study pathogenic genes, susceptibility genes, and disease-specific protein biomarkers.
Focuses on early diagnostic markers and drug resistance genes in malignant tumors and complex diseases.
Achievements and Capabilities:
Instrumentation:
Equipped with advanced instruments including the SEILD protein fingerprinting system, next-generation gene sequencers, RT-PCR, microdialysis systems, nucleic acid protein analyzers, laser scanning confocal microscopy systems, and microwave extractors.
Possesses over 10 million yuan worth of proteomics research equipment, including the CiphergenPBSⅡC protein fingerprint detection system, gene sequencers, and Caliper1000 microfluidic chip analysis systems.
Established technical platforms for SEILDI-TOF-MS, MALDI-TOF-MS, and ITRAQ proteomics research.
Research Outputs:
Secured over 30 national and provincial research grants.
Received four provincial and ministerial-level scientific and technological achievement awards.
Filed and obtained over 30 national patents.
Published more than 60 academic papers.
Specific Research Projects:
Integrated Diagnostic and Therapeutic Nanomolecular Robots:
Focuses on developing DNA nanorobots with fluorescent nanosensor-targeted inhibition functions for cancer diagnosis and treatment.
Aims to elucidate the anti-tumor mechanisms of nanorobots, optimize intervention strategies, and study toxicity responses for early, rapid diagnosis and targeted clinical treatment of malignant tumors.
Early Molecular Diagnosis, Pathogenesis, and New Target Research:
Uses molecular medical techniques to systematically study pathogenic and susceptibility genes, and disease-specific protein biomarkers in diseases like gastric cancer, liver cancer, diabetes, and chronic kidney disease.
Emphasizes research on early diagnostic markers and resistance genes in malignant tumors.
Integrative Non-Invasive Molecular Diagnosis Technology:
Explores new integrative diagnostic models combining traditional Chinese and Western medicine.
Conducts non-invasive molecular diagnosis research using salivary proteomics for diseases like gastric cancer, liver cancer, diabetes, and chronic kidney disease.
Aims to establish new integrative non-invasive molecular diagnostic pathways and models, and apply them in clinical diagnosis.
